Biodesix, Inc. announced that it has entered into a new master collaborative research agreement (MCRA) with Memorial Sloan Kettering Cancer Center (MSK) under which the teams will collaborate on a development plan for diagnostic tests aimed at improving the treatment of cancer. Biodesix will utilize its array of genomics, proteomics, and data mining capabilities with the aim of developing and commercializing oncology biomarker assays in collaboration with MSK. Bio-Rad will provide its industry-leading digital PCR assay technology in support of this important work.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.57 USD | 0.00% | +5.69% | -14.13% |
May. 13 | TD Cowen Starts Biodesix With Buy Rating, $2.80 Price Target | MT |
May. 08 | Transcript : Biodesix, Inc., Q1 2024 Earnings Call, May 08, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.13% | 178M | |
-22.04% | 8.54B | |
+68.10% | 4.32B | |
-0.82% | 2.53B | |
-39.22% | 2.48B | |
-9.49% | 1.9B | |
-18.74% | 1.59B | |
-40.70% | 1.23B | |
+13.38% | 1.13B | |
+16.15% | 994M |
- Stock Market
- Equities
- BDSX Stock
- News Biodesix, Inc.
- Biodesix Announces New Master Collaborative Research Agreement with Memorial Sloan Kettering Cancer Center